Regulation & Policy

©Getty Images - Ildo Frazao

FDA’s takedown of NMN raises fairness, transparency concerns

By Hank Schultz

NMN, an anti-aging ingredient, has been disallowed by FDA because of its prior investigation as a drug. The determination, which came as something of a surprise given the ingredient’s market history, has raised questions of fairness and transparency.

Health and nutrition regulatory updates from China, New Zealand, India, Thailand

Regulatory review: Updates from China, New Zealand, India, Thailand

By Tingmin Koe

China seeking new methods to test laxatives, beta-blockers in health foods, New Zealand industry body objecting government’s recommendations to schedule levomefolate, and India’s mandatory traceability policy on vegan products are some of the latest APAC...

Follow us


View more